Paris (France) and Cambridge (Massachusetts, U.S.), May 27, 2026, at 11:00 p.m. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies impacting longevity, Biophytis provides an update on the modification of the terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first time on February 26, 2026, and amended a second time on May 22, 2026. These changes are part of Biophytis’ strategy to optimize its financial structure and secure the resources needed to achieve its clinical ambitions.
Stanislas Veillet, CEO of Biophytis, stated: “The adjustments to our Hexagon financing facility reflect active and disciplined financial management in support of our strategy. By making this facility revolving and reducing its cost, we are giving ourselves valuable flexibility to finance our next steps under the best conditions. Biophytis is entering a pivotal period this year with the launch of our joint venture in Hong Kong, which will mark the concrete start of our Phase 3 study in sarcopenia – a world first. We are continuing our development methodically, with a sound financial structure and renewed ambition in the therapeutic potential of our drug candidate and our platform.”
